Where science meets the deal table. This highly differentiated profitable investment bank is built exclusively for life sciences and healthcare, advising biopharma, medtech, diagnostics and related healthcare companies on M&A, capital raising and strategic transactions. Senior bankers with deep sector and transaction experience run every engagement themselves, from the first conversation through closing, and position each asset for strategic and financial buyers, while long-standing client relationships generate repeat and referral mandates. The firm has been profitable on a reported basis in every year from 2023 through 2025 with a mid-20s average reported EBITDA margin, and management projects 2026 at roughly $6.1MM in revenue and $2.0MM in reported EBITDA. Management has also identified roughly $8MM of success fees across six mandates expected to close by the first quarter of 2027, none of which is included in the 2026 projection. Reported results include certain non-recurring items, detailed in the CIM. Revenue combines advisory fees that are not contingent on a closing with success fees earned at closing, giving the business a fee base between transactions and upside when deals close.
The owners are seeking a strategic or financial partner to acquire the business and will reinvest approximately $6.0MM of their sale proceeds back into the business at closing to fund a well-defined and market-aligned growth plan with a clear path to liquidity. The buyer will control how it is deployed, so senior leadership stays invested in what comes next. Confidentiality is paramount in a relationship-driven business, so the location and identity of the Business will be shared once a qualified buyer is vetted.
NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.
